TD Cowen initiated a $24 price target for Roivant Sciences (ROIV) following the release of its announcement that its Brepo 30mg dose succeeded in Ph3 VALOR DM with robust and consistent statistical signifiant efficacy on all key endpoints.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $20 from $18 at Jefferies
- Roivant Sciences price target raised to $21 from $15 at Guggenheim
- Roivant Sciences price target raised to $20 from $16 at JPMorgan
- Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
- Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis